Cathie Wood's ARK Adjusts ETF Holdings Toward AI and Genomics

Cathie Wood's ARK Invest ETFs made shifts in their holdings last week, according to Seeking Alpha. The report says ARK increased exposure to AI infrastructure, genomic medicine, fintech, and defense tech. Seeking Alpha lists purchases including Tempus AI, Intellia Therapeutics, Natera, Cerebras Systems, and Kodiak AI. The report also says ARK reduced or sold positions in Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), Teradyne, and Twist Bioscience.

Industry-pattern observations: active ETFs reallocating into AI infrastructure and genomics typically amplify capital flows that benefit startups and suppliers in those ecosystems. For AI infrastructure, increased fund interest tends to correlate with greater scrutiny on companies that supply inference accelerators and large-memory hardware. For genomics and AI-driven healthcare, flows often translate into more runway for clinical-stage companies and their ML-enabled diagnostic partners.

portfolio-level reallocations by a large thematic manager like ARK can act as a signal to other investors and may temporarily affect share liquidity for smaller-cap names. However, reported buys and sells in a single week do not by themselves indicate long-term strategic shifts without additional disclosures. Seeking Alpha is the sole source for this weekly update in the scraped material.

For practitioners and market observers: monitor subsequent regulatory filings or ARK fund disclosures for position-size changes, and watch trading volume and short-term price moves in the named companies. Also track hiring, partnership, or product announcements from the bought names for signs that investor interest aligns with operational developments.